www.recomb.eu

RECRUITMENT PROCESS
GENE THERAPY FOR RAG1-SCID
(RECOMB CONSORTIUM)

OPEN CLINICAL TRIAL

Recomb gene therapy

RECOMB consortium

RECOMB is a research consortium started in 2018, which brings together clinical and research professionals from 16 European and 1 Israeli institute with experience in the management of primary immunodeficiencies (PID) or inborn errors of immunity (IEI), such as severe combined immunodeficiency (SCID).
The project received funding from the European Union's Horizon 2020 programme.

RECOMB clinical trial

PHASE I/II

The infant with RAG1-SCID will be admitted to the gene therapy unit of the Vall d'Hebron Barcelona Hospital Campus to receive his treatment, thus avoiding travelling abroad.

The study consists of the infusion of autologous CD34+ cells transduced with the RAG1 lentivirus in patients with SCID due to RAG1 deficiency. The study has already enrolled two patients with satisfactory follow-up of up to two years.

AIM

To offer a new therapeutic option based on gene therapy to newborns and infants with one of the most common forms of SCID: RAG-1 deficiency

CRITERIA

INCLUSION	EXCLUSION
Genetically confirmed RAG1- SCID	HLA-matched donor available
Age below 2 years	Peripheral T cells >300/μL and/or naïve T cells > 1/μL
No HLA-matched donor available	Omenn Syndrome
Peripheral T cells <300/μL and/or naïve T cells < 1/μL	Previous stem cell transplantation
No Omenn Syndrome	Significant organ dysfunction

CONTACT

RAG1 trial study team
PROF. DR. A. C. LANKESTER

rag1trial@lumc.nl
0031715262806
http://www.recomb.eu/

LUMC Leiden University Medical Center